PriceTargets.com logo

NextCure - NXTC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 312.37%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.97 As of 12/20/2024 06:16 PM ET
▲ +0.02 (2.11%)

This chart shows the closing price for NXTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NextCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NXTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NXTC

Analyst Price Target is $4.00
▲ +312.37% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for NextCure in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 312.37% upside from the last price of $0.97.

This chart shows the closing price for NXTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in NextCure. This rating has held steady since October 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightLower TargetBuy ➝ Buy$8.00 ➝ $4.00
8/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
3/22/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $8.00
3/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.00
12/14/2023Needham & Company LLCLower TargetBuy ➝ Buy$6.00 ➝ $4.00
8/8/2023HC WainwrightInitiated CoverageBuy$7.00
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00
3/3/2023Needham & Company LLCReiterated RatingBuy$6.00
12/2/2022Bank of AmericaLower Target$5.00 ➝ $1.00
11/4/2022LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
11/4/2022Needham & Company LLCLower TargetBuy$12.00 ➝ $6.00
11/4/2022Piper SandlerLower TargetOverweight$13.00 ➝ $6.00
8/23/2022Truist FinancialLower TargetBuy$19.00 ➝ $15.00
5/23/2022Piper SandlerLower TargetOverweight$21.00 ➝ $13.00
3/1/2022LADENBURG THALM/SH SHInitiated CoverageBuy$16.00
11/9/2021JMP SecuritiesReiterated RatingHold
11/5/2021Needham & Company LLCLower TargetBuy$30.00 ➝ $14.00
8/18/2021BenchmarkReiterated RatingBuy$17.00
8/9/2021Piper SandlerLower TargetOverweight$26.00 ➝ $21.00
3/9/2021Truist FinancialUpgradeHold ➝ Buy$13.00 ➝ $19.00
3/5/2021Truist FinancialUpgradeHold ➝ Buy$19.00
1/15/2021Bank of AmericaDowngradeNeutral ➝ Underperform$13.00 ➝ $10.00
8/7/2020Needham & Company LLCReiterated RatingBuy$30.00
7/16/2020BenchmarkUpgradeHold ➝ Buy$17.00
7/14/2020BTIG ResearchLower TargetBuy$61.00 ➝ $27.00
7/13/2020Needham & Company LLCReiterated RatingBuy$30.00
7/13/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$11.00
7/13/2020JMP SecuritiesDowngradeOutperform ➝ Market Perform
7/13/2020Piper SandlerLower Target$87.00 ➝ $32.00
7/13/2020Roth CapitalDowngradeBuy ➝ Neutral$15.00
7/13/2020SunTrust BanksDowngradeBuy ➝ Hold$78.00 ➝ $13.00
6/1/2020BenchmarkDowngradeBuy ➝ Hold
6/1/2020Bank of AmericaDowngradeBuy ➝ Neutral$62.00 ➝ $40.00
5/26/2020JMP SecuritiesInitiated CoverageOutperform$55.00
5/8/2020Needham & Company LLCReiterated RatingBuy$72.00
5/8/2020Morgan StanleyLower TargetOverweight$58.00 ➝ $54.00
4/15/2020Morgan StanleyBoost TargetOverweight$55.00 ➝ $58.00
3/24/2020BenchmarkInitiated CoverageBuy$55.00
3/13/2020Needham & Company LLCReiterated RatingBuy$72.00
3/2/2020Roth CapitalInitiated CoverageBuy$80.00
1/13/2020SunTrust BanksInitiated CoverageBuy$78.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

NextCure logo
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Read More

Today's Range

Now: $0.97
Low: $0.93
High: $0.99

50 Day Range

MA: $1.25
Low: $0.89
High: $1.54

52 Week Range

Now: $0.97
Low: $0.87
High: $2.57

Volume

54,790 shs

Average Volume

128,536 shs

Market Capitalization

$27.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of NextCure?

The following Wall Street research analysts have issued reports on NextCure in the last twelve months: HC Wainwright, and Needham & Company LLC.
View the latest analyst ratings for NXTC.

What is the current price target for NextCure?

0 Wall Street analysts have set twelve-month price targets for NextCure in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 312.4%. Needham & Company LLC has the highest price target set, predicting NXTC will reach $4.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $4.00 for NextCure in the next year.
View the latest price targets for NXTC.

What is the current consensus analyst rating for NextCure?

NextCure currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NXTC will outperform the market and that investors should add to their positions of NextCure.
View the latest ratings for NXTC.

What other companies compete with NextCure?

Other companies that are similar to NextCure include Maxpro Capital Acquisition, INmune Bio, X4 Pharmaceuticals, Adverum Biotechnologies and Cardiol Therapeutics. Learn More about companies similar to NextCure.

How do I contact NextCure's investor relations team?

NextCure's physical mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company's listed phone number is (240) 399-4900 and its investor relations email address is [email protected]. The official website for NextCure is www.nextcure.com. Learn More about contacing NextCure investor relations.